Osteoporosis Drug May Lower Osteoarthritis Risk Save
A target trial emulation study using administrative claims suggests that romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis.
Emulating a target trial design, new drug users of romosozumab were compared to teriparatide users who were adults over age ≥50 years, without a prior diagnosis of OA. The primary outcome was the incidence of osteoarthritis.
The study included a total of 22,145 individuals (87% female; mean age, 80 years), 8504 starting romosozumab and 13,641 teriparatide.
Key findings:
- romosozumab had a lower risk of osteoarthritis vs. teriparatide (RR, 0.79 [0.66, 0.89]).
- Especially for knee osteoarthritis (RR, 0.79 (0.66, 0.92)
- There was no significant reduction in either hip OA (RR, 0.68 (0.37, 1.05); or hand OA (RR, 0.61 (0.35, 1.06)
- After 2 years romosozumab users had a lower risk for osteoarthritis than those using oral bisphosphonates (RR, 0.74; 95% CI, 0.61-0.86).
Given this is a claims data, target emulation trial, these findings merit further study and analysis.
Join The Discussion
A ketogenic diet will reduce symptoms of osteoarthritis just as much as other new diabetic drugs have recently demonstrated; As has roux en y gastric bypass and animal studies looking at pioglitazone. This is all because insulin resistance and hyperinsulinemia is the driver of osteoarthritis.
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.